• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于无定形药物稳定化的聚合物筛选方法的小型化筛选方法的比较评估。

Comparative Assessment of Miniaturized Screening Approaches for Selection of Polymers for Amorphous Drug Stabilization.

机构信息

Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, California 94080.

School of Pharmacy, University of Connecticut, Storrs, Connecticut 06269.

出版信息

J Pharm Sci. 2018 Mar;107(3):897-908. doi: 10.1016/j.xphs.2017.11.006. Epub 2017 Nov 16.

DOI:10.1016/j.xphs.2017.11.006
PMID:29155235
Abstract

The present work highlights the use of miniaturized approaches to screen and prioritize development of solid dispersions that provide stabilization of the amorphous drug against crystallization and enhanced dissolution over the crystalline form. The approaches evaluated include solvent casting and solvent displacement-based techniques. Four compounds were evaluated with both these screening approaches. A dual-pH dilution method using fasted state simulated gastric fluid and fasted state simulated intestinal fluid as media was used to evaluate solubility enhancement ratio in each well of the screen. The concentration at 15 mins after dilution with fasted state simulated intestinal fluid and super-saturation ratio at the end of the dissolution study is used as 2 descriptors of solubility enhancement. The empirical screening approaches were supplemented with theoretical calculations of solubility enhancement to gauge the best-performing amorphous solid dispersion (ASD). Physical stability of the amorphous systems was also evaluated, where applicable. Lead ASD compositions from the screens were scaled up to verify the predictions. To our knowledge, this is the first report where the 2 most common screening approaches for the development of ASDs are compared head to head. These approaches are rapid, material sparing, and can be adapted to accommodate screening of multiple variables such as polymer type, drug load, and ternary systems simultaneously. The strengths, limitations, and most suitable applications for each of the 2 methods are also discussed.

摘要

本工作重点介绍了使用微型化方法筛选和优先开发固体分散体,以稳定药物的无定形形式,防止其结晶,并提高其在晶型中的溶解度。评估的方法包括溶剂浇铸和溶剂置换技术。用这两种筛选方法评估了四种化合物。使用双 pH 稀释法,以空腹状态模拟胃液和空腹状态模拟肠液作为介质,评估每个筛选孔中药物溶解度的增强比。稀释后 15 分钟时的浓度和溶解研究结束时的过饱和度比被用作溶解度增强的两个描述符。经验筛选方法与溶解度增强的理论计算相结合,以评估表现最佳的无定形固体分散体 (ASD)。在适用的情况下,还评估了无定形体系的物理稳定性。从筛选中得出的先导 ASD 成分被放大,以验证预测。据我们所知,这是首次将开发 ASD 的两种最常见的筛选方法进行直接比较的报告。这些方法快速、节省材料,并且可以适应同时筛选多种变量,如聚合物类型、药物负载和三元体系。还讨论了每种方法的优缺点以及最适合的应用领域。

相似文献

1
Comparative Assessment of Miniaturized Screening Approaches for Selection of Polymers for Amorphous Drug Stabilization.用于无定形药物稳定化的聚合物筛选方法的小型化筛选方法的比较评估。
J Pharm Sci. 2018 Mar;107(3):897-908. doi: 10.1016/j.xphs.2017.11.006. Epub 2017 Nov 16.
2
Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.聚合物无定形固体分散体:生物药剂学分类系统II类药物的非晶化、结晶、稳定化、固态表征及水相增溶综述
J Pharm Sci. 2016 Sep;105(9):2527-2544. doi: 10.1016/j.xphs.2015.10.008. Epub 2016 Jan 23.
3
Amorphous solid dispersion of nisoldipine by solvent evaporation technique: preparation, characterization, in vitro, in vivo evaluation, and scale up feasibility study.溶剂蒸发技术制备硝苯地平无定形固体分散体:制备、表征、体外、体内评价及放大可行性研究。
Drug Deliv Transl Res. 2020 Aug;10(4):903-918. doi: 10.1007/s13346-020-00775-8.
4
Classification of solid dispersions: correlation to (i) stability and solubility (ii) preparation and characterization techniques.固体分散体的分类:与(i)稳定性和溶解性(ii)制备及表征技术的相关性
Drug Dev Ind Pharm. 2015;41(9):1401-15. doi: 10.3109/03639045.2015.1018274. Epub 2015 May 20.
5
Navigating the Solution to Drug Formulation Problems at Research and Development Stages by Amorphous Solid Dispersion Technology.利用无定形固体分散技术解决研发阶段的药物制剂问题。
Recent Adv Drug Deliv Formul. 2024;18(2):79-99. doi: 10.2174/0126673878271641231201065151.
6
Solubility advantage from amorphous etoricoxib solid dispersions.无定形依托考昔固体分散体的溶解度优势。
Drug Dev Ind Pharm. 2014 Jan;40(1):92-101. doi: 10.3109/03639045.2012.749887. Epub 2013 Jan 10.
7
Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.药物-聚合物的溶解度和混溶性:无定形固体分散体开发中的稳定性考虑和实际挑战。
J Pharm Sci. 2010 Jul;99(7):2941-7. doi: 10.1002/jps.22074.
8
Amorphous stabilization and dissolution enhancement of amorphous ternary solid dispersions: combination of polymers showing drug-polymer interaction for synergistic effects.无定形三元固体分散体的无定形稳定化与溶出度增强:具有药物 - 聚合物相互作用以产生协同效应的聚合物组合
J Pharm Sci. 2014 Nov;103(11):3511-3523. doi: 10.1002/jps.24137. Epub 2014 Sep 5.
9
Miniaturized screening of polymers for amorphous drug stabilization (SPADS): rapid assessment of solid dispersion systems.用于无定形药物稳定化的聚合物微型筛选 (SPADS):固体分散体系统的快速评估。
Eur J Pharm Biopharm. 2013 Aug;84(3):583-98. doi: 10.1016/j.ejpb.2013.01.009. Epub 2013 Feb 8.
10
Recent Advances in Understanding the Micro- and Nanoscale Phenomena of Amorphous Solid Dispersions.理解无定形固体分散体的微观和纳米现象的最新进展。
Mol Pharm. 2019 Oct 7;16(10):4089-4103. doi: 10.1021/acs.molpharmaceut.9b00601. Epub 2019 Sep 5.

引用本文的文献

1
Modeling and Simulation of Process Technology for Nanoparticulate Drug Formulations-A Particle Technology Perspective.纳米颗粒药物制剂工艺技术的建模与仿真——颗粒技术视角
Pharmaceutics. 2020 Dec 24;13(1):22. doi: 10.3390/pharmaceutics13010022.
2
High-Throughput Dissolution/Permeation Screening -A 96-Well Two-Compartment Microplate Approach.高通量溶出/渗透筛选——一种96孔双室微孔板方法。
Pharmaceutics. 2019 May 10;11(5):227. doi: 10.3390/pharmaceutics11050227.